Try our beta test site
5 studies found for:    lymphoma [CONDITION] OR CLL [CONDITION] | Open Studies | Ublituximab
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Interventions: Drug: Ublituximab + TGR-1202;   Drug: Ublituximab + TGR-1202 + ibrutinib;   Drug: Ublituximab + TGR-1202 + bendamustine
Phase: Phase 1
Number Enrolled: 140
2 Recruiting Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma
Interventions: Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202
Phases: Phase 2 / Phase 3
Number Enrolled: 200
3 Recruiting An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Interventions: Biological: ublituximab;   Drug: TGR-1202
Phase: Phase 2
Number Enrolled: 300
4 Recruiting Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
Interventions: Drug: Pembrolizumab;   Drug: TGR-1202;   Biological: ublituximab
Phases: Phase 1 / Phase 2
Number Enrolled: 12
5 Recruiting Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Interventions: Biological: Obinutuzumab;   Biological: Ublituximab;   Drug: TGR-1202;   Drug: Chlorambucil
Phase: Phase 3
Number Enrolled: 450

Study has passed its completion date and status has not been verified in more than two years.